Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cytokine

• Publication date

  2011-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.cyto.2011.06.005PMID 21742513
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models

  2011cited by this paper
• Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.

  2010cited by this paper
• Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.

  2010influential reference
• Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

  2010cited by this paper
• Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs

  2009cited by this paper
• Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer.

  2009cited by this paper
• Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.

  2009cited by this paper
• Tumor Immunotherapy in Melanoma

  2008cited by this paper
• Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

  2008cited by this paper
• The Interleukin-8 Pathway in Cancer

  2008influential reference
• Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-κB Transcription and Evasion of Apoptosis

  2008cited by this paper
• Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells

  2007cited by this paper
• Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma.

  2007influential reference
• Reciprocal regulation of 5α-dihydrotestosterone, Interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma

  2007cited by this paper
• Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.

  2007cited by this paper
• A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.

  2007cited by this paper
• Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer.

  2006cited by this paper
• Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.

  2006cited by this paper
• Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

  2006cited by this paper
• Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.

  2006cited by this paper
• Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.

  2005cited by this paper
• Chemokines in tumor progression and metastasis

  2005cited by this paper
• The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

  2005cited by this paper
• Predictive value of serum interleukin‐8 levels in ovarian cancer patients treated with paclitaxel‐containing regimens

  2005cited by this paper
• Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

  2005influential reference
• Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.

  2005cited by this paper
• Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models*

  2004cited by this paper
• Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients.

  2004cited by this paper
• Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin.

  2004cited by this paper
• Ovarian cancer: strategies for overcoming resistance to chemotherapy

  2003cited by this paper
• Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

  2002cited by this paper
• Expression of metastasis-related genes in human epithelial ovarian tumors.

  2002cited by this paper
• Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel*

  2002cited by this paper
• [Cytokine].

  2001cited by this paper
• Interleukin-8 and human cancer biology.

  2001cited by this paper
• Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology.

  2001cited by this paper
• Interleukin‐8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel‐containing chemotherapy

  2001cited by this paper
• Interleukin 8: an autocrine growth factor for human ovarian cancer.

  2001cited by this paper
• Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.

  2001cited by this paper
• P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

  2000cited by this paper
• Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.

  2000influential reference
• Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.

  2000cited by this paper
• Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.

  2000cited by this paper
• Upregulation of interleukin‐8 and polarized epithelial expression of interleukin‐8 receptor A in ovarian carcinomas

  2000cited by this paper
• Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line*

  1999cited by this paper
• Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.

  1999cited by this paper
• Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.

  1999cited by this paper
• Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.

  1999cited by this paper
• Cxc chemokine receptor expression on human endothelial cells.

  1999cited by this paper
• Regulation of Interleukin-8 Gene Expression

  1999cited by this paper
• The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?

  1998cited by this paper
• Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.

  1998cited by this paper
• The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.

  1995cited by this paper
• Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF.

  1989cited by this paper
• Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes.

  1987cited by this paper
• Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales.

  1986cited by this paper

• Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer.

  2026cites this paper
• Acquisition of drug-resistance induces cytokine reprogramming in a human leukemic cell line. Role of p38 MAPK.

  2026cites this paper
• FRY Mediates THP1-Driven Ovarian Cancer Invasion Through the PI3K/AKT Pathway

  2026cites this paper
• The role of cytokines in ovarian cancer drug resistance

  2025cites this paper
• Quantification of intrinsic MDR-1 gene expression in different immunophenotypes of canine multicentric lymphomas.

  2025cites this paper
• Role of interleukin-6 in resistance to tumor therapy

  2025cites this paper
• The role of diet and nutraceuticals in the amelioration of multidrug resistance amongst cancer patients

  2025cites this paper
• Immunohistochemical Study of IL-6 and IL-10 Expression in Breast Cancer Correlations with ER, PR, Her-2, Ki-67, and Clinicopathological Features in Iraqi Women

  2025cites this paper
• Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer

  2025cites this paper
• The Role of Exosomes as a Key Factor of Cytostatic Resistance in Cancer: Mechanisms of Action, Potential Biomarkers, and Possible Exosome-Based Therapies

  2025cites this paper
• Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics

  2025cites this paper
• Chemotherapy as a double‐edged sword: Modulation of tumor‐associated cytokine and chemokine responses in ovarian cancer

  2025cites this paper
• Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks

  2025cites this paper
• The IL-8/NF-κB feedback loop confers a paclitaxel-sensitive/doxorubicin-resistant phenotype in triple-negative breast cancer.

  2025cites this paper
• Role of Neutrophils in Homeostasis and Diseases

  2025cites this paper
• Cisplatin Toxicity Causes Neutrophil-Mediated Inflammation in Zebrafish Larvae

  2024cites this paper
• Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer

  2024cites this paper
• Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells

  2024cites this paper
• Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas

  2024cites this paper
• Hyaluronic acid-functionalized ruthenium photothermal nanoenzyme for enhancing osteosarcoma chemotherapy: Cascade targeting and bidirectional modulation of drug resistance.

  2024cites this paper
• Co-Colorectal cancer stem cells employ the FADS1/DDA axis to evade NK cell-mediated immunosuppression after co-cultured with NK cells under hypoxia

  2024cites this paper
• Novel insights into immune cells modulation of tumor resistance.

  2024cites this paper
• tRNA modifications and tRNA-derived small RNAs: new insights of tRNA in human disease

  2024cites this paper
• The diverse influences of relaxin-like peptide family on tumor progression: Potential opportunities and emerging challenges

  2024cites this paper
• Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options

  2024cites this paper
• Clonal differences underlie variable responses to sequential and prolonged treatment.

  2024cites this paper
• Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer

  2024cites this paper
• Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer

  2023cites this paper
• Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance.

  2023cites this paper
• CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)

  2023cites this paper
• Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat.

  2023cites this paper
• A 3D multi-cellular tissue model of the human omentum to study the formation of ovarian cancer metastasis.

  2023cites this paper
• Effects of Pleiotrophin (PTN) on the resistance to paclitaxel in ovarian cancer cells

  2023cites this paper
• Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway.

  2023cites this paper
• Clonal differences underlie variable responses to sequential and prolonged treatment

  2023cites this paper
• Crossroad between the Heat Shock Protein and Inflammation Pathway in Acquiring Drug Resistance: A Possible Target for Future Cancer Therapeutics

  2023cites this paper
• tRNA derived fragments:A novel player in gene regulation and applications in cancer

  2023cites this paper
• Interleukin-6 and Hypoxia Synergistically Promote EMT-Mediated Invasion in Epithelial Ovarian Cancer via the IL-6/STAT3/HIF-1α Feedback Loop

  2023cites this paper
• Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses

  2023cites this paper
• The inhibitory effect of Gremlin-2 on adipogenesis suppresses breast cancer cell growth and metastasis

  2023cites this paper
• IL-6/JAK2-dependent G6PD phosphorylation promotes nucleotide synthesis and supports tumor growth

  2023cites this paper
• Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer

  2022cites this paper
• The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination

  2022cites this paper
• Interleukin-6 Signaling in Triple Negative Breast Cancer Cells Elicits the Annexin A1/Formyl Peptide Receptor 1 Axis and Affects the Tumor Microenvironment

  2022cites this paper
• Combined inhibition of IL-6 and IL-8 pathways suppresses ovarian cancer cell viability and migration and tumor growth

  2022cites this paper
• LncRNALOXL1-AS1 Regulates the Proliferation and Apoptosis of Ovarian Cancer Cells by Targeting miR-761

  2022cites this paper
• Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations

  2022influential citation
• Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer

  2022cites this paper
• Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models

  2022cites this paper
• Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines

  2022cites this paper
• Small secretory proteins of immune cells can modulate gynecological cancers.

  2022cites this paper
• Role of RAS signaling in ovarian cancer

  2022cites this paper
• Identification of two theranostic biomarker panels for epithelial ovarian cancer.

  2022cites this paper
• Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion

  2022cites this paper
• Gene polymorphisms of Interleukin 6 (−174 G/C) and transforming growth factor β-1(+915 G/C) in ovarian cancer patients

  2022cites this paper
• Role of exosomes in the immune microenvironment of ovarian cancer

  2021cites this paper
• Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance

  2021cites this paper
• IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

  2021cites this paper
• Targeting the tumour microenvironment in platinum-resistant ovarian cancer.

  2021cites this paper
• Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells

  2021cites this paper
• Quantitative phosphoproteomic analysis reveals chemoresistance-related proteins and signaling pathways induced by rhIL-6 in human osteosarcoma cells

  2021cites this paper
• Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation

  2021cites this paper
• Therapeutic strategies to overcome taxane resistance in cancer.

  2021cites this paper
• An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer

  2021cites this paper
• Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model

  2021cites this paper
• CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.

  2021cites this paper
• Assessment of clinical variables as predictive markers in the development and progression of colorectal cancer

  2021cites this paper
• The Influence of Let-7b-5p Target Gene in Cholangiocarcinoma and its Bioinformatic Analysis

  2021cites this paper
• C-reactive protein promotes tongue squamous cell carcinoma chemoresistance by inhibiting the activation of caspase-3/9 via the CD64/AKT/mTOR pathway

  2021cites this paper
• CXCR2 As a Novel Target for Overcoming Resistance to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Cells

  2021cites this paper
• Vasculogenic Mimicry in Breast Cancer: Clinical Relevance and Drivers

  2021cites this paper
• TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.

  2021cites this paper
• The Problem of Drug Resistance in Cancer Chemotherapy

  2020cites this paper
• Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance

  2020cites this paper
• Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer

  2020cites this paper
• Expression of genes involved in the inflammatory response in human granulosa cells in short-term in vitro culture

  2020cites this paper
• Adipocytes: active facilitators in epithelial ovarian cancer progression?

  2020cites this paper
• Different mechanisms underlie IL-6 release in chemosensitive and chemoresistant ovarian carcinoma cells.

  2020cites this paper
• IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells.

  2020cites this paper
• Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?

  2020cites this paper
• Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function

  2020cites this paper
• Ultrasound-Augmented Phase Transition Nanobubbles for Targeted Treatment of Paclitaxel-Resistant Cancer.

  2020cites this paper
• TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells.

  2020cites this paper
• Cancer‐associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer

  2020cites this paper
• CMAR_A_278903 11897..11908

  2020cites this paper
• Mechanisms of Multidrug Resistance in Cancer Chemotherapy

  2020cites this paper
• miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells

  2020cites this paper
• Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells

  2020cites this paper
• Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer

  2020cites this paper
• Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors

  2019cites this paper
• Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer

  2019cites this paper
• Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells

  2019cites this paper
• Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.

  2019cites this paper
• Chemotherapy and Inflammatory Cytokine Signalling in Cancer Cells and the Tumour Microenvironment.

  2019cites this paper
• miR‐29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1

  2019cites this paper
• MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma

  2019cites this paper
• Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment

  2019cites this paper
• Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors

  2019cites this paper
• TLR4-Induced Inflammation Is a Key Promoter of Tumor Growth, Vascularization, and Metastasis

  2019influential citation
• The Potential Role of Interleukin-11 in Epithelial Ovarian Cancer

  2019cites this paper